Psychedelic Assisted Therapy (psilocybin, MDMA-assisted therapy in research settings)

Overview

What It Is Psychedelic-assisted therapy involves supervised administration of compounds such as psilocybin or MDMA within a structured psychotherapeutic framework that includes preparation, dosing sessions, and integration. Research has focused on treatment-resistant depression, PTSD, and end-of-life distress.

How It Works These compounds can temporarily increase psychological flexibility and, in the case of classic psychedelics, promote a window of heightened synaptic plasticity. Psychotherapy before, during, and after dosing aims to help patients process material and consolidate new perspectives while that window is open—combining pharmacological plasticity with intentional learning.

Conditions - Research / limited legal settings: treatment-resistant depression (psilocybin), PTSD (MDMA-assisted therapy), and end-of-life distress. - Note: Access remains limited to trials or jurisdictions with specific legal frameworks. Medical and psychological screening and careful set-and-setting are essential for safety.

How it is administered

Supervised sessions in research or specialized clinical settings. Includes preparation, dosing sessions with trained facilitators, and integration therapy afterward.

Conditions connected in the NPA database

The NPA Treatment Database lists this treatment in connection with 3 condition records. A database relationship does not establish effectiveness, safety, or suitability for an individual.

• Clinical Depression
• Post Traumatic Stress Disorder (PTSD)
• Anxiety Disorders

Related questions

These controlled question pages reference this treatment through stored condition relationships.

• What treatments are listed for Anxiety Disorders in the NPA database?
• What treatments are listed for Clinical Depression in the NPA database?
• What treatments are listed for Post Traumatic Stress Disorder (PTSD) in the NPA database?

Symptoms connected in the NPA database

The current record associates this treatment with the following symptom information. This is not a claim that the treatment will improve these symptoms.

Practical information

Results and outcomes described in the source record

Psychological shifts can occur during/after sessions; lasting change often requires integration work.

Side effects and risks

Psychological risks (anxiety, challenging experiences); physical risks depend on substance and screening. Legal and regulatory restrictions apply.

Research context in the NPA database

Research summary

Evidence Level: Emerging (research settings)

What the research shows: Early-to-mid stage clinical trials show promising results for treatment-resistant depression (psilocybin) and PTSD (MDMA-assisted therapy). These treatments remain largely investigational or restricted.

Key takeaway: Potentially powerful options that are currently available mainly through research trials or limited legal frameworks, with careful medical and psychological screening required.

Research detail

Overview Psychedelic-assisted therapy involves the supervised administration of compounds such as psilocybin or MDMA within a structured psychotherapeutic framework that includes preparation, dosing sessions, and integration. Research has focused on treatment-resistant depression, PTSD, and end-of-life distress. Sessions occur in controlled clinical or research settings with trained facilitators. The psychological effects are profound and can include altered perception, emotional release, and shifts in perspective; integration work afterward is considered essential for lasting benefit.

Evidence Base and Published Work • Phase 2 and 3 trials of psilocybin for treatment-resistant depression and MDMA-assisted therapy for PTSD have shown promising results. • Systematic reviews of psychedelic-assisted therapy document both potential benefits and the still largely investigational status. • Key published work includes: – Phase 2 and 3 trials of psilocybin for depression and MDMA-assisted therapy for PTSD. – Systematic reviews of psychedelic-assisted therapy (still largely investigational). – Treatments remain restricted to research trials or limited legal frameworks. Psychological and medical screening, careful set-and-setting, and integration work are considered essential for safety.

Outcomes in early-to-mid stage trials include promising results for treatment-resistant depression (psilocybin) and PTSD (MDMA-assisted therapy). These treatments remain largely investigational or restricted.

Questions to ask a provider

1. Am I eligible for a clinical trial or legal supervised psychedelic-assisted therapy for my condition (e.g., treatment-resistant depression, PTSD)? 2. What preparation, dosing-session support, and integration therapy are included? 3. What medical and psychiatric screening is required, and what are the key risks? 4. What outcomes have phase 2/3 trials shown for people with a profile similar to mine? 5. What is the legal status and total cost in the setting where treatment would occur?